In recent years, the concept of "cardiometabolic risk" is increasingly used in clinical practice. One of the most common diseases is non-alcoholic fatty liver disease (NAFLD) - a chronic liver disease that is considered as a component of some diseases associated with insulin resistance. The development of NAFLD on the background of comorbid pathology is closely associated with an increase in the degree of cardiometabolic risk, which can determine the prognosis and life expectancy of patients.The monograph presents the results of our own studies that demonstrated the involvement of "new" markers - C-reactive protein, tumor necrosis factor- , endothelial dysfunction indicators such as: circulating desquamated endothelial cells, vascular endothelial growth factor and telomere length in the formation of cardiometabolic changes in patients with NAFLD on the background of subclinical hypothyroidism, which can lead to early vascular aging. The data obtained expands our understanding of cardiometabolic risk formation mechanisms, to predict the course of the disease and to individualize the strategy for the prevention of cardiovascular events in a comorbid patient.